Akoya Biosciences Inc (AKYA) concluded trading on Wednesday at a closing price of $1.30, with 17.27 million shares of worth about $22.44 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -46.06% during that period and on May 21, 2025 the price saw a gain of about 22.64%. Currently the company’s common shares owned by public are about 49.84M shares, out of which, 20.81M shares are available for trading.
Stock saw a price change of 37.46% in past 5 days and over the past one month there was a price change of 11.11%. Year-to-date (YTD), AKYA shares are showing a performance of -43.23% which decreased to -54.39% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.93 but also hit the highest price of $3.42 during that period. The average intraday trading volume for Akoya Biosciences Inc shares is 489.13K. The stock is currently trading 12.62% above its 20-day simple moving average (SMA20), while that difference is up 1.70% for SMA50 and it goes to -41.37% lower than SMA200.
Akoya Biosciences Inc (NASDAQ: AKYA) currently have 49.84M outstanding shares and institutions hold larger chunk of about 24.66% of that.
The stock has a current market capitalization of $64.84M and its 3Y-monthly beta is at 1.37. It has posted earnings per share of -$0.96 in the same period. It has Quick Ratio of 0.40. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for AKYA, volatility over the week remained 7.71% while standing at 8.64% over the month.
Analysts are in expectations that Akoya Biosciences Inc (AKYA) stock would likely to be making an EPS of -0.23 in the current quarter, while forecast for next quarter EPS is -0.2 and it is -0.5 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.23 which is -0.23 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.27 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 30.80% while it is estimated to increase by 19.68% in next year. EPS is likely to grow at an annualized rate of 22.40% for next 5-years, compared to annual growth of -23.03% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Craig Hallum on November 15, 2024 offering a Hold rating for the stock and assigned a target price range of between $7 and $5 to it. Stock get a Buy rating from Craig Hallum on June 21, 2024.
